EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?

Klaus Schmierer iD, Frederick Chen, David Paling iD

European Journal of Neurology · 2026-07 · 33 (7)

DOI: 10.1111/ene.70698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 06.07.2026. Verfasst von Klaus Schmierer und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Blizard Institute, Queen Mary University of London, Faculty of Medicine & Dentistry, London, UK. Hauptthemen laut MEDLINE: Blood Transfusion, Cladribine, Graft vs Host Disease, Immunosuppressive Agents. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Irradiation of cellular blood components prevents transfusion‐associated graft‐versus‐host disease (TA‐GVHD). UK and Spanish guidance recommend lifelong irradiation for all patients treated with purine analogues, including cladribine, irrespective of indication or dose.

Objective

To assess whether this approach is justified for people with multiple sclerosis (pwMS) receiving cladribine.

Methods

Narrative synthesis of immunological data, hemovigilance evidence, and national European transfusion guidelines.

Results

Cladribine used in pwMS induces transient lymphopenia with modest, reversible T‐cell effects and preserved vaccine responsiveness. Since introduction of universal pre‐storage leucocyte depletion, hemovigilance data show no reported cases of TA‐GVHD in this setting. European guidance is heterogeneous, ranging from indefinite to time‐limited or unspecified durations.

Conclusion

Current evidence does not clearly support the need for lifelong irradiation after cladribine treatment in pwMS. Time‐limited or individualized approaches merit consideration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood TransfusionCladribineGraft vs Host DiseaseImmunosuppressive AgentsMultiple SclerosisTransfusion ReactionHumans

Stichwörter der Autor:innen

cladribinedisease modifying therapiesmultiple sclerosistransfusion‐associated graft‐versus‐host disease

Substanzen

CladribineImmunosuppressive Agents

Autor:innen und Institutionen

  • The Blizard Institute, Queen Mary University of London, Faculty of Medicine & Dentistry, London, UK.
  • Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
  • Clinical Haematology, The Royal London Hospital, Barts Health NHS Trust, London, UK.
  • Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK.

ORCID-Profile: Klaus Schmierer, David Paling

Zitieren

APA

Schmierer, K., Chen, F., & Paling, D. (2026). Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?. European Journal of Neurology, 33(7). https://doi.org/10.1111/ene.70698

Vancouver

Schmierer K, Chen F, Paling D. Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?. European Journal of Neurology. 2026;33(7). doi:10.1111/ene.70698

BibTeX
@article{Schmierer2026,
  author = {Schmierer, Klaus and Chen, Frederick and Paling, David},
  title = {Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1111/ene.70698}
}
Kostenlos starten →